帕罗培特立帕肽(Palopegteriparatide) - 药物靶点：CaSR x PTH1R_在研适应症：甲状旁腺功能减退症_专利_临床

概要

基本信息

药物类型

合成多肽

别名

TransCon parathyroid hormone、TransCon PTH、TransCon-PTH

+ [4]

靶点

CaSR x PTH1R

作用方式

拮抗剂、调节剂、刺激剂

作用机制

CaSR拮抗剂(钙敏感受体拮抗剂)、PTH1R调节剂(甲状旁腺激素受体调节剂)、骨生成刺激剂

治疗领域

内分泌与代谢疾病

在研适应症

甲状旁腺功能减退症

非在研适应症-

原研机构

Ascendis Pharma A/S

在研机构

Ascendis Pharma Bone Diseases A/S

Ascendis Pharma A/SSpecialised Therapeutics Australia Pty Ltd.

+ [3]

非在研机构-

权益机构

Teijin Pharma Ltd.

维昇药业（上海）有限公司Specialised Therapeutics Asia Pte Ltd.

+ [4]

最高研发阶段批准上市

首次获批日期

欧盟 (2023-11-17),

甲状旁腺功能减退症

最高研发阶段(中国)临床3期

特殊审评优先审评 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、孤儿药 (英国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

Sequence Code 4953

来源: *****

关联

13

项与帕罗培特立帕肽相关的临床试验

NCT07081997

/ Not yet recruiting临床3期

A Phase 3, Multicenter, Single Arm, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 µg/Day in Adult Participants With Hypoparathyroidism

This trial has a duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.

开始日期2025-11-01

申办/合作机构

Ascendis Pharma Bone Diseases A/S

JPRN-jRCT2051210058

/ Not yet recruiting临床3期IIT

A Phase 3, Multicenter, Single Arm, Open-Label Trial, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Japanese Adult Subjects with Hypoparathyroidism - PaTHway Japan Trial

开始日期2021-11-02

申办/合作机构-

NCT05387070

/ Recruiting临床3期

PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

This study is limited to conduct in China only. The primary objective is to assess the treatment effect of daily TransCon PTH on serum calcium (sCa) levels within the normal range and stopping from therapeutic doses of active vitamin D (calcitriol) or active vitamin D analogue (alfacalcidol) and calcium at 26 weeks of treatment. All subjects will start with 18 mcg of study drug and will be individually and progressively titrated to an optimal dose over a 26-week double blind period, followed by an open label extension period up to 156 weeks. TransCon PTH or placebo will be administered as a subcutaneous injection using a pre-filled injection pen. Neither trial participants nor their doctors will know who has been assigned to each group. After the 26 weeks, participants will continue in the trial as part of a long-term extension study. During the extension, all participants will receive TransCon PTH, with the dose adjusted to their individual needs.

开始日期2021-07-28

申办/合作机构

维昇药业（上海）有限公司

100 项与帕罗培特立帕肽相关的临床结果

登录后查看更多信息

100 项与帕罗培特立帕肽相关的转化医学

登录后查看更多信息

100 项与帕罗培特立帕肽相关的专利（医药）

登录后查看更多信息

7,294

项与帕罗培特立帕肽相关的文献（医药）

2026-01-01·JOURNAL OF ETHNOPHARMACOLOGY

Pien-Tze-Huang ameliorates autoimmune hepatitis by promoting hepatocyte autophagy via inhibiting miR-342-3p/mTOR signal

Article

作者: Wang, Yang ; Liu, Miaohua ; Xiong, Yi ; Zeng, Xin ; Zheng, Linxin ; Liu, Duanyong ; Li, Shanshan ; Zhou, Bugao

ETHNOPHARMACOLOGICAL RELEVANCE:

Pien Tze Huang (PTH), as a national protected species with a history of more than 450 years, is known for its efficacy in heat clearance, detoxification, blood cooling, blood stasis removal, and is commonly used in the treatment of liver-related diseases. However, it remains unclear whether PTH regulates autophagy by modulating miR-342-3p/mTOR signaling pathway for the treatment of autoimmune hepatitis (AIH).

AIM OF THE STUDY:

To explore the therapeutic effects and molecular mechanisms of PTH on AIH, focusing on the analysis of its regulatory effects on miR-342-3p/mTOR pathway and autophagy.

MATERIALS AND METHODS:

The chemical composition of PTH was analyzed by LC-MS/MS; AIH model was constructed in C57BL/6J mice to assess the effects of PTH on symptoms, pathological damage and cytokines; lysosomal changes were observed by transmission electron microscopy, and autophagy-related proteins (LC3B, Beclin-1) expression was detected; differential miRNAs and mRNAs were screened by whole-transcriptome sequencing and verified by RT-PCR for key miRNAs and mRNAs (miR-342-3p); induction of AML-12 hepatocyte inflammation model, combined with autophagy modeling experiments, lentivirus-mediated overexpression/knockdown of miR-342-3p and mTOR pathway interventions, to further clarify the molecular mechanism of PTH for AIH.

RESULTS:

PTH is mainly composed of amino acids and their derivatives, lipids and organic acids; PTH intervention significantly improved the symptoms of AIH mice, attenuated liver injury, regulated cytokines, and promoted lysosomal restitution and autophagy protein expression. Whole transcriptome sequencing and experiments confirmed that PTH downregulated miR-342-3p, inhibited mTOR signaling and enhanced autophagy. Cellular experiments further demonstrated that PTH activated autophagy and alleviated inflammation by directly regulating the miR-342-3p/mTOR axis.

CONCLUSION:

Pien-Tze-Huang ameliorates autoimmune hepatitis by promoting hepatocyte autophagy via inhibiting miR-342-3p/mTOR signal. This study elucidates a clear molecular mechanism for PTH's therapeutic action, highlighting its potential as a targeted treatment for AIH, and the miR-342-3p/mTOR axis serves as a viable target for future anti-AIH drug design.

2025-12-31·CLINICAL AND EXPERIMENTAL HYPERTENSION

Parathyroid hormone and vitamin D modulate nocturnal blood pressure dipping: a retrospective cohort study in primary hypertension

Article

作者: Liang, Xiaohui ; Xu, Yixin ; Deng, Changjiang

BACKGROUND:

Non-dipper hypertension, defined by reduced nocturnal blood pressure (BP) decline, increases cardiovascular risk. Calcium-phosphate metabolism (parathyroid hormone [PTH], vitamin D [25(OH)D]) may influence circadian BP rhythms, but their independent roles remain unclear.

OBJECTIVE:

To investigate associations between PTH, 25(OH)D, and nocturnal BP dipping in primary hypertension, addressing prior inconsistencies.

METHODS:

This retrospective cohort included 585 hypertensive adults stratified by nocturnal systolic BP dipping (dippers [≥10% decline, n = 250]; non-dippers [<10%, n = 335]) using 24-hour ambulatory monitoring. Serum PTH, 25(OH)D, renal/metabolic parameters, and vascular indices were analyzed. Multivariate linear regression assessed associations with dipping, adjusted for age, sex, renal function, and arterial stiffness.

RESULTS:

Non-dippers showed elevated PTH (median: 5.23 vs. 4.70 pmol/L, p = .011) and lower 25(OH)D (30.89 vs. 36.79 nmol/L, p < .001). Adjusted models confirmed PTH (β=-0.21, 95% CI:-0.34--0.08; p = .002) and 25(OH)D (β = 0.03, 95% CI:0.01-0.04; p < .001) as associated factors of dipping. Although statistically significant, these correlations were modest and suggested possible trends rather than strong causal relationships. Age/sex effects on BP patterns became nonsignificant after adjusting for calcium-phosphate markers.

CONCLUSION:

Calcium-phosphate dysregulation (elevated PTH, low vitamin D) independently contributes to non-dipping, suggesting biomarker-guided approaches for circadian BP control. Demographic disparities in dipping may reflect underlying mineral metabolism disturbances. Prospective trials should explore calcium-modulating therapies (e.g. vitamin D supplementation) in non-dipper hypertension.

2025-12-31·ANNALS OF MEDICINE

Is it true that lower PTH control is associated with lower levels of inflammatory cytokines in patients with chronic kidney disease?

Article

作者: Fengmin, Shao ; Huixia, Cao ; Shasha, Wang ; Yifeng, Hu ; Qin, Xu ; Qiuyue, Xiong ; Ning, Wang ; Lei, Yan

BACKGROUND:

The body of patients with chronic kidney disease (CKD)is in a state of microinflammation, which further aggravates the progression of CKD and the occurrence and development of its complications. The inflammatory state of the body is significantly increased in patients with secondary hyperparathyroidism of CKD.

METHODS:

Patients diagnosed with chronic kidney disease in the department of Nephrology of Henan Provincial People's Hospital were selected as the experimental group, and 58 normal subjects were selected as the control group. Collecting patient's Clinical date, whole blood of the experimental group and control group was collected, and hs-CRP was detected by enzyme-linked immunosorbent assay. Compare the differences in clinical indicators and serum hs-CRP between the two groups. Taking PTH and hs-CRP as dependent variables, correlation analysis was conducted to clarify the relationship between PTH and hs-CRP, and further curve fitting was carried out.

RESULTS:

The levels of hemoglobin, total protein and albumin in CKD group were significantly lower than those in control group (p < 0.001). Alkaline phosphatase, creatinine, uric acid, Cyc and blood phosphorus in CKD group were higher than those in control group, and the P values were 0.016, <0.001, <0.001, <0.001, <0.001, respectively. Blood calcium was lower than control group, p < 0.001. The levels of hs-CRP in CKD group were significantly higher than those in control group, p < 0.001. Serum PTH was positively correlated with serum hs-CRP (r = 0.299, p = 0.002) in a normalized holistic analysis of CKD patients. In order to further clarify the correlation between PTH and hs-CRP, quadratic method was used to conduct curve fitting on PTH and hs-CRP and found that R = 0.361, F = 7.795, p < 0.001. Quadratic method was used to quadratic curve fitting at PTH levels <600 pg/mL, <500 pg/mL, <400 pg/mL, <300 pg/mL and <200 pg/mL, respectively, and it was found that the corresponding R = 0.281, F = 4.158, p < 0.001. R = 0.292, F = 4.397, p < 0.001; R = 0.546, F = 18.456, p < 0.001; R = 0.415, F = 7.471, p < 0.001; R = 0.403, F = 5.220, p < 0.001. It was found that there was no correlation between PTH and hs-CRP in hemodialysis patients and peritoneal dialysis patients. In order to exclude the influence of drug use on the statistical results, after excluding the patients who took over phosphorus binder and calcium binder, curve fitting method was used to find that PTH and CRP were correlated, in peritoneal dialysis group and hemodialysis group, R = 0.953, F = 39.913, p < 0.001; R = 0.448, F = 3.391, p = 0.010 respectively.

CONCLUSION:

CKD patients have the lowest levels of inflammatory factors within a certain range of PTH.

209

项与帕罗培特立帕肽相关的新闻（医药）

2025-10-21

·Global Tech Nexus

苹果股价冲新高，iPhone 17首销暴增14%

全球热点报告详细分析报告时间范围：2025年10月20日至 2025年10月21日类别：商业与金融一、医药与生物科技1. Genentech 获批治疗狼疮性肾炎新药 Gazyva（奥比妥珠单抗）事件概要：美国 FDA 批准了由罗氏子公司 Genentech 开发的 Gazyva（obinutuzumab），用于治疗狼疮性肾炎。这是一种严重的狼疮并发症，影响肾脏功能。临床数据：在一项三期临床试验中，接受 Gazyva 治疗的患者中有 46.4% 达到了主要终点，显示出显著疗效。给药方式：第一年需进行四次静脉输注，之后每年两次。意义：这是治疗狼疮性肾炎的重大进展，有望改善患者生活质量并减少对传统免疫抑制剂的依赖。2. Ascendis Pharma 药物 Yorvipath 报告患者死亡事件背景：Ascendis Pharma 的股票在 10 月 20 日下跌近 12%，因 FDA 不良事件数据库更新显示一名服用其药物 Yorvipath（用于治疗甲状旁腺功能减退症）的患者死亡。公司回应：Ascendis Pharma 尚未发布正式声明，但 FDA 表示该事件为严重不良事件，并未确认药物与死亡之间的直接因果关系。市场反应：尽管股价一度大幅下挫，但收盘时跌幅收窄至 2.5%。二、企业财报与业绩1. 主要公司财报发布预告发布日期：10 月 20 日开盘前重点公司：Verizon (VZ)、可口可乐 (KO)、3M (MMM)、通用汽车 (GM)、洛克希德·马丁 (LMT)、GE、霍尼韦尔 (HAL)、诺斯罗普·格鲁曼 (NOC)、卡特彼勒 (PCAR) 等。市场预期：投资者密切关注这些公司的盈利表现，以判断宏观经济走势和行业趋势。2. Apple 股价创新高驱动因素：iPhone 17 在美国和中国市场销售强劲，首十天销量比 iPhone 16 高出 14%。技术升级：新机型在芯片、显示屏、存储容量和摄像头方面均有提升，且价格保持不变。市场反应：苹果股价上涨近 4%，收盘价达 262.24 美元的历史新高。三、能源与资源1. 美国与澳大利亚签署关键矿物协议合作方：美国与澳大利亚政府投资规模：项目管道总额达 85 亿美元，其中双方将在六个月内各投入 10 亿美元。战略目标：减少对中国稀土和其他关键矿物的依赖，加强本土供应链建设。具体项目：包括在美国资助澳大利亚稀土加工设施等。2. Alcoa 与美澳共建镓工厂参与方：Alcoa、美国政府、澳大利亚政府地点：澳大利亚西澳州 Wagerup 氧化铝精炼厂目的：保障半导体和高科技产业所需的关键材料供应，减少对外依赖。3. Kinder Morgan 与 Phillips 66 提议加州燃料管道项目内容：从德州向加州、亚利桑那州和内华达州输送成品油的新管道系统。目的：提高西部地区燃料供应稳定性，降低运输成本。下一步计划：启动公开招标以吸引潜在承运商。四、金融市场动态1. 油价跌至五个月低位原因：全球供应过剩担忧加剧中美贸易紧张局势持续能源需求疲软市场影响：原油期货价格大幅下挫，相关 ETF（如 USO）也受到冲击。2. ServisFirst Bancshares 贷款增长预期乐观Q3 表现：贷款增长未达预期，但贷款管道同比增长 40%，预示 Q4 增长潜力。利率环境：美联储降息有助于降低存款成本，预计净息差将每季度扩张 7-10 个基点。风险管理：虽然非履约资产有所增加，但管理层表示整体风险可控。五、科技与人工智能1. Anthropic 推出 Claude for Life Sciences产品定位：专为生命科学研究设计的 AI 平台，整合 Benchling、PubMed 等研究工具。应用场景：文献综述、实验设计、监管文件撰写等。战略意义：Anthropic 正式进入生命科学领域，拓展其 AI 应用边界。2. OpenAI 加强对 Sora 2 深度伪造内容管控触发事件：演员 Bryan Cranston 和 SAG-AFTRA 对 AI 生成其形象和声音的视频表示担忧。应对措施：OpenAI 承诺与相关机构合作，加强对生成内容的审核和控制。未来方向：可能引入更严格的用户身份验证机制和内容标识系统。3. AWS 大规模服务中断影响航空业故障时间：10 月 20 日凌晨开始，持续约一天受影响服务：DynamoDB 数据库问题导致 EC2 实例无法启动，影响多个网站和服务受影响企业：达美航空和联合航空的在线值机系统瘫痪恢复情况：AWS 宣布服务已恢复正常，但仍存在部分延迟六、政治与政策1. 特朗普呼吁乌克兰割让领土给俄罗斯会议背景：特朗普与乌克兰总统泽连斯基在白宫举行会谈特朗普立场：建议乌克兰接受俄罗斯对顿巴斯地区的控制以结束战争国际反应：此举引发广泛争议，被认为是对乌克兰主权的严重挑战2. 特朗普获准部署国民警卫队至波特兰法院裁决：联邦上诉法院推翻下级法院禁令，允许特朗普调动国民警卫队保护 ICE 设施理由：抗议活动频繁干扰联邦执法机构运作法律依据：援引允许总统在常规力量不足时调动国民警卫队的联邦法律3. 政府停摆或将于本周结束官方表态：白宫经济顾问 Kevin Hassett 称停摆可能在本周内结束政治博弈：共和党希望短期拨款法案维持现状，民主党则等待“无王日”抗议后采取行动七、社会与经济观察1. 罗斯指数揭示单身人士宜居城市方法论：根据房租不超过总收入 30% 的标准计算“Carrie Bradshaw 指数”结果：41 个城市被评为“不可负担”，较去年增加 3 个推荐城市：德克萨斯州的达拉斯、休斯顿和奥斯汀等地成为单身人士较易负担的选择2. 电动车贬值速度快于燃油车数据来源：iSeeCars 研究显示，电动车五年内平均贬值率比燃油车高 13%主要原因：初始购车激励削弱二手车价值快速的技术迭代使旧车型迅速过时目标消费群体偏向高端市场，限制了大众市场需求八、总结与展望1. 医药创新持续推进Genentech 在自身免疫疾病治疗领域的突破，预示着未来更多精准疗法的出现。2. 关键矿物争夺战升温美澳合作凸显全球关键资源供应链重构趋势，中国在全球稀土市场的主导地位面临挑战。3. AI 技术加速渗透各行各业Anthropic 和 OpenAI 在生命科学和内容安全领域的布局，展现了 AI 商业化的新方向。4. 地缘政治风险持续发酵特朗普对乌克兰的强硬态度和对国内抗议的应对，反映出美国政治极化和社会分裂的加剧。5. 经济复苏仍存不确定性尽管部分板块表现亮眼，但油价下跌、政府停摆和地缘冲突等因素仍对全球经济构成压力。本报告全面梳理了过去 24 小时内全球商业领域的重大事件，涵盖医药、能源、科技、金融、政治等多个维度，旨在为读者提供深入、系统的分析视角。

临床3期财报

2025-09-24

·医药地理

全球首个！帕罗培特立帕肽获批博鳌落地

9 月 23 日，维昇药业宣布，其创新药物帕罗培特立帕肽（palopegteriparatide，TransCon PTH）正式在海南博鳌乐城获批，作为临床急需药物用于治疗成人慢性甲状旁腺功能减退症（HP，俗称“甲旁减”）。首批患者将在上海交通大学医学院附属瑞金医院海南医院率先用药。这也是全球首个、目前唯一获批的 HP 激素替代疗法，为长期缺乏规范治疗手段的患者带来新选择。 HP 是由于甲状旁腺激素（PTH）分泌不足引起的代谢性疾病，中国约有 40 万潜在患者。传统治疗主要依赖大剂量钙剂和活性维生素 D 来维持血钙水平，虽然能够缓解低钙血症，但无法逆转 PTH 缺乏导致的代谢异常和长期并发症，疗效始终有限。与传统“补钙+维生素”不同，PTH 替代疗法直击病因，通过补充缺失的 PTH，让体内激素水平稳定在正常生理范围。它不仅能改善短期症状，还能在骨骼健康和肾功能方面带来长期获益，被视为更符合生理机制的理想治疗路径。帕罗培特立帕肽依托 TransCon（暂时连接）技术，实现长效释放，模拟人体 24 小时的自然 PTH 水平，从而同时改善短期症状与长期并发症。全球已积累超过 4 年的临床数据，显示该药在维持血钙正常的同时，能持续改善骨密度与肾功能，安全性与有效性均获得验证。其在博鳌乐城的落地，标志着我国在内分泌罕见病治疗领域迈出关键一步。 END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

2025-09-24

·丁香园 Insight 数据库

全球首个！又一临床急需新药落地海南博鳌

9 月 23 日，维昇药业宣布其创新药物帕罗培特立帕肽（palopegteriparatide, TransCon PTH）正式获得海南博鳌乐城国际医疗旅游先行区批准，作为临床急需药品用于治疗成人慢性甲状旁腺功能减退症（HP，简称甲旁减），在上海交通大学医学院附属瑞金医院海南医院应用于临床使用。新闻稿指出，帕罗培特立帕肽是全球首款也是目前唯一一款获批的甲状旁腺功能减退症激素替代疗法，填补了我国在 HP 激素替代治疗领域的长期空白。截图来源：企业官微 HP 是一种由于甲状旁腺激素（PTH）分泌不足而引起的一组临床综合征。中国存在潜在 40 万患者群体。传统治疗方法为大剂量口服补充钙剂和活性维生素 D 或类似物，旨在将血钙维持在正常范围下限或略低于正常范围。这类疗法可在一定程度上缓解低钙血症症状，但无法从根本上解决 PTH 缺乏所引起的代谢异常和并发症。相对于传统对症治疗方案，PTH 替代疗法针对病因，通过补充缺失的 PTH，将 PTH 水平持续稳定在正常生理范围内，是更符合生理的理想 HP 治疗方案。帕罗培特立帕肽通过创新的 TransCon(暂时连接) 技术突破成药壁垒，旨在恢复每天 24 小时内 PTH 的生理水平，以同时改善该疾病引起的短期症状和长期并发症。在全球范围内，帕罗培特立帕肽已积累长达 4 年的长期数据，进一步证实了该药的长期安全性和有效性，包括在持续治疗期间，患者在维持正常血钙水平的情况下，可同时实现骨骼健康及肾脏功能的改善。封面来源：企业 Logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：馨药 PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn

核酸药物

100 项与帕罗培特立帕肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	H05AA	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
甲状旁腺功能减退症	欧盟	Ascendis Pharma Bone Diseases A/S	2023-11-17
甲状旁腺功能减退症	冰岛	Ascendis Pharma Bone Diseases A/S	2023-11-17
甲状旁腺功能减退症	列支敦士登	Ascendis Pharma Bone Diseases A/S	2023-11-17
甲状旁腺功能减退症	挪威	Ascendis Pharma Bone Diseases A/S	2023-11-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04701203 (PaTHway, Company_Website) 人工标引	临床3期	甲状旁腺功能减退症	73	Palopegteriparatide	鏇淵襯鏇構夢構築製餘(鹹顧淵醖鹽襯艱壓構繭) = 範鏇淵淵積醖製夢觸顧鏇選糧構淵鏇壓醖範蓋 (築繭簾衊蓋鏇鑰顧顧餘 ) 更多	积极	2025-07-14
NCT04009291 (PaTH Forward, NEWS \| Corporate Publications) 人工标引	临床2期	甲状旁腺功能减退症	56	Palopegteriparatide	願遞鑰鬱壓淵鹽壓襯鹹(醖鬱餘製淵遞積顧衊遞) = 選壓窪艱願淵膚鏇憲淵觸簾選鏇構壓淵願蓋鏇 (餘衊鬱衊壓製齋蓋獵窪 ) 更多	积极	2025-05-18
NCT04701203 (PaTHway, CTgov)	临床3期	甲状旁腺功能减退症	84	TransCon PTH (TransCon PTH)	餘襯鏇憲繭構壓鏇遞壓 = 膚齋衊選鹹鹹壓壓簾簾蓋鹽壓製鹹廠醖網簾獵 (鹽廠顧獵鹹顧範襯積顧, 築鏇鹹窪觸鬱夢鬱夢膚 ~ 鑰蓋範鹹範顧鹹築糧膚) 更多	-	2025-02-28
				Placebo (Placebo)	餘襯鏇憲繭構壓鏇遞壓 = 繭顧衊壓觸遞襯遞繭廠蓋鹽壓製鹹廠醖網簾獵 (鹽廠顧獵鹹顧範襯積顧, 廠艱繭鹹壓淵選窪觸繭 ~ 積顧艱製壓夢構壓鏇網) 更多
NCT05387070 (PaTHway, PRNewswire) 人工标引	临床3期	甲状旁腺功能减退症	-	Palopegteriparatide	鏇憲艱餘鏇簾夢網襯範(衊蓋獵繭鑰築觸顧簾艱) = 鹹蓋鏇鑰觸艱窪窪膚繭獵廠壓繭鏇構壓構醖餘 (鏇鏇鬱願簾衊獵蓋鹽鑰 ) 更多	积极	2024-08-12
				Placebo	鏇憲艱餘鏇簾夢網襯範(衊蓋獵繭鑰築觸顧簾艱) = 積積襯襯壓艱構願廠範獵廠壓繭鏇構壓構醖餘 (鏇鏇鬱願簾衊獵蓋鹽鑰 )
NCT04701203 (FDA_CDER) 人工标引	临床3期	甲状旁腺功能减退症	82	YORVIPATH	膚壓壓鹽膚願齋醖簾選(鏇餘餘膚艱鑰齋範艱簾) = 顧齋艱壓窪顧願繭鹹夢觸艱觸艱觸醖鑰範齋廠 (鹹膚廠鹹願積鬱淵網艱 ) 更多	积极	2024-08-09
				Placebo	膚壓壓鹽膚願齋醖簾選(鏇餘餘膚艱鑰齋範艱簾) = 範築築鹽鏇鹽繭鏇憲鑰觸艱觸艱觸醖鑰範齋廠 (鹹膚廠鹹願積鬱淵網艱 ) 更多
NCT04701203 (PaTHway, GlobeNewswire) 人工标引	临床3期	甲状旁腺功能减退症	82	TransCon PTH (palopegteriparatide)	鏇鹹遞鬱製衊簾夢觸遞(積願衊築顧遞獵蓋積簾) = 鑰遞廠鏇鬱餘顧積襯願獵糧鬱繭願窪遞繭衊鬱 (獵廠獵鏇願廠醖夢鏇繭 ) 更多	积极	2024-05-13
				TransCon PTH (palopegteriparatide) (eGFR < 60 mL/min/1.73m2)	鏇鹹遞鬱製衊簾夢觸遞(積願衊築顧遞獵蓋積簾) = 鑰蓋鏇齋願製艱醖糧夢獵糧鬱繭願窪遞繭衊鬱 (獵廠獵鏇願廠醖夢鏇繭 ) 更多
NCT04009291 \| NCT04701203 \| NCT05387070 (PaTHway, ENDO2023)	临床3期	甲状旁腺功能减退症	82	TransCon PTH	夢齋遞選廠齋願製餘鏇(範齋鏇鑰襯觸齋糧廠鹹) = trended toward norms from baseline to Weeks 26 and 52 壓構繭襯壓範觸鬱積夢 (膚鏇壓醖夢繭積鹽鬱遞 ) 更多	积极	2023-10-05
PaTH Forward Trial (ENDO2022)	临床2期	甲状旁腺功能减退症	59	TransCon PTH 15 mcg/d	糧鹹夢簾獵衊顧夢製鹹(齋淵繭構窪鹹鹹鏇構窪) = 製醖糧醖願鏇鬱積蓋窪艱膚夢願積壓蓋鹹膚艱 (壓選餘鬱襯選糧獵顧積 ) 更多	积极	2022-11-01
				TransCon PTH 18 mcg/d	糧鹹夢簾獵衊顧夢製鹹(齋淵繭構窪鹹鹹鏇構窪) = 鑰蓋醖觸鬱糧鏇鹹構觸艱膚夢願積壓蓋鹹膚艱 (壓選餘鬱襯選糧獵顧積 ) 更多
NCT04009291 \| NCT04701203 \| NCT05387070 (PaTHway, ENDO2022)	临床3期	甲状旁腺功能减退症	82	TransCon PTH 18 mcg/d	淵艱鬱窪齋鹹艱築衊鏇(願鏇糧築選憲築襯夢構) = The most commonly reported study drug-related AEs were headaches 遞鬱淵窪獵壓夢鏇膚鑰 (鏇窪夢糧憲觸衊鏇顧顧 ) 更多	积极	2022-11-01
				Placebo
NCT04009291 (PaTH Forward, Corporate Publications) 人工标引	临床2期	-	57	TransCon™ PTH	襯衊衊獵蓋鏇窪膚製範(糧鑰鬱壓繭艱遞鹽繭獵) = 襯鏇壓蓋齋衊遞壓窪願齋醖艱範膚膚網廠鹽醖 (獵鬱餘製憲壓艱獵網壓 ) 更多	积极	2022-09-12